HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Mutational analysis of the tyrosine kinome in serous and clear cell endometrial cancer uncovers rare somatic mutations in TNK2 and DDR1.

AbstractBACKGROUND:
Endometrial cancer (EC) is the 8th leading cause of cancer death amongst American women. Most ECs are endometrioid, serous, or clear cell carcinomas, or an admixture of histologies. Serous and clear ECs are clinically aggressive tumors for which alternative therapeutic approaches are needed. The purpose of this study was to search for somatic mutations in the tyrosine kinome of serous and clear cell ECs, because mutated kinases can point to potential therapeutic targets.
METHODS:
In a mutation discovery screen, we PCR amplified and Sanger sequenced the exons encoding the catalytic domains of 86 tyrosine kinases from 24 serous, 11 clear cell, and 5 mixed histology ECs. For somatically mutated genes, we next sequenced the remaining coding exons from the 40 discovery screen tumors and sequenced all coding exons from another 72 ECs (10 clear cell, 21 serous, 41 endometrioid). We assessed the copy number of mutated kinases in this cohort of 112 tumors using quantitative real time PCR, and we used immunoblotting to measure expression of these kinases in endometrial cancer cell lines.
RESULTS:
Overall, we identified somatic mutations in TNK2 (tyrosine kinase non-receptor, 2) and DDR1 (discoidin domain receptor tyrosine kinase 1) in 5.3% (6 of 112) and 2.7% (3 of 112) of ECs. Copy number gains of TNK2 and DDR1 were identified in another 4.5% and 0.9% of 112 cases respectively. Immunoblotting confirmed TNK2 and DDR1 expression in endometrial cancer cell lines. Three of five missense mutations in TNK2 and one of two missense mutations in DDR1 are predicted to impact protein function by two or more in silico algorithms. The TNK2(P761Rfs*72) frameshift mutation was recurrent in EC, and the DDR1(R570Q) missense mutation was recurrent across tumor types.
CONCLUSIONS:
This is the first study to systematically search for mutations in the tyrosine kinome in clear cell endometrial tumors. Our findings indicate that high-frequency somatic mutations in the catalytic domains of the tyrosine kinome are rare in clear cell ECs. We uncovered ten new mutations in TNK2 and DDR1 within serous and endometrioid ECs, thus providing novel insights into the mutation spectrum of each gene in EC.
AuthorsMeghan L Rudd, Hassan Mohamed, Jessica C Price, Andrea J O'Hara, Matthieu Le Gallo, Mary Ellen Urick, NISC Comparative Sequencing Program, Pedro Cruz, Suiyuan Zhang, Nancy F Hansen, Andrew K Godwin, Dennis C Sgroi, Tyra G Wolfsberg, James C Mullikin, Maria J Merino, Daphne W Bell
JournalBMC cancer (BMC Cancer) Vol. 14 Pg. 884 (Nov 26 2014) ISSN: 1471-2407 [Electronic] England
PMID25427824 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, N.I.H., Intramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
Chemical References
  • Poly-ADP-Ribose Binding Proteins
  • DDR1 protein, human
  • Discoidin Domain Receptor 1
  • Protein-Tyrosine Kinases
  • Receptor Protein-Tyrosine Kinases
  • TNK2 protein, human
  • DNA Polymerase II
  • POLE protein, human
Topics
  • Adenocarcinoma, Clear Cell (genetics, pathology)
  • Cell Line, Tumor
  • Cystadenocarcinoma, Serous (genetics, pathology)
  • DNA Copy Number Variations
  • DNA Mutational Analysis
  • DNA Polymerase II (genetics)
  • Discoidin Domain Receptor 1
  • Endometrial Neoplasms (genetics, pathology)
  • Female
  • Humans
  • Microsatellite Instability
  • Mutation
  • Neoplasm Grading
  • Poly-ADP-Ribose Binding Proteins
  • Protein Interaction Domains and Motifs (genetics)
  • Protein-Tyrosine Kinases (genetics)
  • Receptor Protein-Tyrosine Kinases (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: